CDRE vs. NARI, PRCT, NVST, NVCR, IRTC, LIVN, WRBY, ENOV, TNDM, and TMDX
Should you be buying Cadre stock or one of its competitors? The main competitors of Cadre include Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), NovoCure (NVCR), iRhythm Technologies (IRTC), LivaNova (LIVN), Warby Parker (WRBY), Enovis (ENOV), Tandem Diabetes Care (TNDM), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.
Cadre vs.
Inari Medical (NASDAQ:NARI) and Cadre (NYSE:CDRE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
91.0% of Inari Medical shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by insiders. Comparatively, 37.0% of Cadre shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Cadre has lower revenue, but higher earnings than Inari Medical. Inari Medical is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.
Cadre has a net margin of 6.34% compared to Inari Medical's net margin of -13.68%. Cadre's return on equity of 12.88% beat Inari Medical's return on equity.
Inari Medical currently has a consensus price target of $68.00, indicating a potential downside of 14.52%. Cadre has a consensus price target of $39.75, indicating a potential upside of 3.99%. Given Cadre's stronger consensus rating and higher probable upside, analysts plainly believe Cadre is more favorable than Inari Medical.
Inari Medical received 50 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 57.89% of users gave Inari Medical an outperform vote while only 55.17% of users gave Cadre an outperform vote.
Inari Medical has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Cadre has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
In the previous week, Cadre had 10 more articles in the media than Inari Medical. MarketBeat recorded 12 mentions for Cadre and 2 mentions for Inari Medical. Cadre's average media sentiment score of 0.46 beat Inari Medical's score of 0.06 indicating that Cadre is being referred to more favorably in the news media.
Summary
Cadre beats Inari Medical on 12 of the 17 factors compared between the two stocks.
Get Cadre News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:CDRE) was last updated on 1/21/2025 by MarketBeat.com Staff
